Pairidex welcomes Eric Green, M.D., Ph.D., former director of the National Human Genome Research Institute (NHGRI) at the U.S. National Institutes of Health (NIH) from 2009 to 2025 as an Advisor.

Dr. Green guided work aimed at improving our understanding of human genetics and using those findings to help develop treatments for genetic diseases.  Dr. Green will provide valuable input as Pairidex expands testing for fusion-driven blood cancers.

Before becoming head of the institute, discoveries from Green’s lab contributed to the Human Genome Project. His research team also uncovered the genetic causes driving multiple diseases, such as Pendred syndrome, a rare disorder that can lead to hearing loss.  Throughout his career, Dr. Green has authored and co-authored over 390 scientific publications.

Pairidex has developed a proprietary novel droplet digital PCR assay providing personalized measurable residual disease detection for fusion-driven blood cancers. “Our sensitive assays allow researchers to gauge therapeutic success long before traditional endpoints, shortening trial timelines and increasing confidence in new therapies” according to Andrew Young, Founder and CSO.